MXC: $0.073
What We Make

MGC Pharma operates in several different segments of the Medical Cannabis industry.

MGC Pharma applies high standards of QA and QC to different segments of the Medical Cannabis industry, allowing us to meet and exceed Good Manufacturing Practice (GMP) and GACP protocols, globally. Our company operates three pioneering divisions.

MGC Botanic

The Botanic Division engages with multiple cultivation sites to meet increasing global demand, alongside research into breeding and genetics with leading institutions and academia. We will continue to harvest the product in Slovenia and Czech Republic, and use the raw material at our production facility, as well as provide the product globally.

Our research & development:

  • We’re excited to embark on a University of Ljubljana botanic research to develop new genetic strains.
  • Refining and steadying MGC Pharma’s genetic bank to balance indications and treatment, and to guarantee our ability to produce flawless, high quality products all over the globe.  
  • We’ve partnered with Academy of Science, Czech Republic, on numerous strain grows.
MGC Innovation

The Innovation Division is focused on our medical product pipeline and is our largest division. This division focuses on products that emerge from our supply line. These include neutraceuticals, which will be able to provide the additional needs and requirements that our body demands on a daily basis to improve our immune system, detoxify and enhance wellness.

Additionally, this includes our extracts, at various levels of purity, and with the ability to extract various phytocannabinoids and terpenes to the level of Active Pharmaceutical Ingredient.

The Innovation division is  focused on three specific areas of treatment:

  • Neurological disorders, which includes MGC Pharma’s proprietary formulations for Epilepsy
  • Oncological care and treatment
  • Autoimmune diseases, via taking advantage of the various anti-inflammatory benefits our products have on the body.
MGC Derma

MGC Derma is our skincare and anti-aging line for day-to-day use. We are currently working on a new line of dermatological products called DermaPlus, which is already presenting impressive results from clinical studies. MGC Derma is a pioneering CBD cosmetic brand with distribution deals signed in various markets, presently in deliberations to engage in new markets.

MGC Derma produces CBD enhanced cosmetics, DermaPlus dermatological line and private label manufacturing.

Our research & development:

  • Derma Plus product range clinical tests finalized with the three products showing strong improvement in the skin conditions tests.
  • Launch of product line in UK, Australia and USA planned for 2018.
Our three pioneering divisions allow MGC to be a key player in all significant levels of production in various global locations. It also allows MGC to progress with simultaneous high level research and development, clinical trials around the world and to embrace new emerging verticals in CBD markets.